These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. CD39 overexpression does not attenuate renal fibrosis in the unilateral ureteric obstructive model of chronic kidney disease. Roberts V; Lu B; Chia J; Cowan PJ; Dwyer KM Purinergic Signal; 2016 Dec; 12(4):653-660. PubMed ID: 27565966 [TBL] [Abstract][Full Text] [Related]
4. CD39 deficiency in murine liver allografts promotes inflammatory injury and immune-mediated rejection. Yoshida O; Dou L; Kimura S; Yokota S; Isse K; Robson SC; Geller DA; Thomson AW Transpl Immunol; 2015 Mar; 32(2):76-83. PubMed ID: 25661084 [TBL] [Abstract][Full Text] [Related]
5. Natural killer T cell dysfunction in CD39-null mice protects against concanavalin A-induced hepatitis. Beldi G; Wu Y; Banz Y; Nowak M; Miller L; Enjyoji K; Haschemi A; Yegutkin GG; Candinas D; Exley M; Robson SC Hepatology; 2008 Sep; 48(3):841-52. PubMed ID: 18752325 [TBL] [Abstract][Full Text] [Related]
6. Modulation of nucleoside [correction of nucleotide] triphosphate diphosphohydrolase-1 (NTPDase-1)cd39 in xenograft rejection. Imai M; Takigami K; Guckelberger O; Enjyoji K; Smith RN; Lin Y; Csizmadia E; Sévigny J; Rosenberg RD; Bach FH; Robson SC Mol Med; 1999 Nov; 5(11):743-52. PubMed ID: 10656876 [TBL] [Abstract][Full Text] [Related]
7. Liver grafts from CD39-overexpressing rodents are protected from ischemia reperfusion injury due to reduced numbers of resident CD4+ T cells. Pommey S; Lu B; McRae J; Stagg J; Hill P; Salvaris E; Robson SC; d'Apice AJ; Cowan PJ; Dwyer KM Hepatology; 2013 Apr; 57(4):1597-606. PubMed ID: 22829222 [TBL] [Abstract][Full Text] [Related]